Relay Therapeutics (NASDAQ:RLAY) CFO Sells $105,308.40 in Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 13,820 shares of the firm’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total transaction of $105,308.40. Following the sale, the chief financial officer owned 250,996 shares in the company, valued at $1,912,589.52. The trade was a 5.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Thomas Catinazzo also recently made the following trade(s):

• On Wednesday, January 28th, Thomas Catinazzo sold 1,695 shares of Relay Therapeutics stock. The stock was sold at an average price of $8.45, for a total transaction of $14,322.75.

Relay Therapeutics Stock Down 0.6%

NASDAQ:RLAY opened at $7.66 on Friday. The business’s 50-day simple moving average is $7.97 and its two-hundred day simple moving average is $5.99. Relay Therapeutics, Inc. has a 52 week low of $1.77 and a 52 week high of $9.04. The stock has a market cap of $1.33 billion, a PE ratio of -4.38 and a beta of 1.55.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). Sell-side analysts anticipate that Relay Therapeutics, Inc. will post -2.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on RLAY. Weiss Ratings reissued a “sell (d-)” rating on shares of Relay Therapeutics in a report on Friday, January 9th. Oppenheimer upgraded shares of Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 price target on the stock in a report on Monday, January 26th. Finally, Wells Fargo & Company raised shares of Relay Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $6.00 to $13.00 in a report on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Relay Therapeutics has an average rating of “Moderate Buy” and an average target price of $16.57.

Key Stories Impacting Relay Therapeutics

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: Technical/quote signal — MarketBeat notes an intraday uptick and that shares are trading above the 200‑day moving average, a constructive technical sign that can attract momentum buyers. MarketBeat RLAY quote
• Positive Sentiment: Analyst support — Recent upgrades (Oppenheimer to Outperform; Wells Fargo to Overweight) and a consensus “Moderate Buy” rating give fundamental/flow support that can limit downside from short‑term selling. Analyst commentary
• Neutral Sentiment: Insiders still hold large stakes — filings show executives retain hundreds of thousands of shares after the sales, so these transactions reduce ownership modestly but are not a change of control signal. (See SEC filings for details.) SEC ownership filing
• Negative Sentiment: CFO selling — CFO Thomas Catinazzo sold 13,820 shares on Jan. 27 (~$105k at ~$7.62) and an additional 1,695 shares on Jan. 28 (~$14.3k at ~$8.45). Multi‑day sales by the CFO amplify concerns and can sap near‑term sentiment. Catinazzo filings
• Negative Sentiment: Other insider sales clustered over Jan. 27–28 — Director/executive Peter Rahmer sold ~11.7k and 1,354 shares across two days; Donald Bergstrom sold ~18.9k and 2,686 shares. The concentration and timing of sales by multiple insiders increase short‑term selling pressure. Rahmer filings Bergstrom filings
• Negative Sentiment: Market commentary citing a notable intraday decline (~5.2%) amplifies negative sentiment and may trigger momentum selling even if fundamentals are unchanged. Why RLAY is down 5.18%

Institutional Trading of Relay Therapeutics

Large investors have recently made changes to their positions in the business. Torren Management LLC purchased a new stake in shares of Relay Therapeutics during the 4th quarter valued at about $30,000. FNY Investment Advisers LLC increased its stake in Relay Therapeutics by 100.0% during the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock worth $34,000 after acquiring an additional 5,000 shares during the last quarter. Quinn Opportunity Partners LLC purchased a new stake in Relay Therapeutics during the second quarter valued at approximately $35,000. May Hill Capital LLC bought a new stake in shares of Relay Therapeutics in the 2nd quarter valued at approximately $38,000. Finally, Focus Partners Advisor Solutions LLC purchased a new position in shares of Relay Therapeutics in the 2nd quarter worth approximately $39,000. 96.98% of the stock is currently owned by institutional investors.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.